VRTX

Vertex Pharmaceuticals
D

VRTX

440.90
USD
1.12
(0.25%)
مفتوح الان
حجم التداول
44,202
الربح لكل سهم
18
العائد الربحي
-
P/E
-232
حجم السوق
113,503,459,275
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأفكار والتحليلات
    هشام منسي
    هشام منسي
    منذ 5 أشهر
    buy
    VRTX
    VRTX
    2024-08-22 10:31
    VRTX Chart
    المزيد
أصول ذات صلة
    AMGN
    AMGN
    -1.30
    (-0.47%)
    276.57 USD
    BIIB
    BIIB
    1.490
    (1.04%)
    145.180 USD
    B
    BMRN
    -0.240
    (-0.39%)
    61.850 USD
    E
    EXEL
    -2.140
    (-6.27%)
    31.990 USD
    GILD
    GILD
    0.230
    (0.25%)
    93.140 USD
    I
    INCY
    0.180
    (0.25%)
    72.720 USD
    I
    IONS
    -0.070
    (-0.20%)
    34.360 USD
    REGN
    REGN
    -14.24
    (-2.05%)
    680.12 USD
    المزيد
الأخبار
المقالات

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.